Skip to main content
Midas Edge

Indivior Pharmaceuticals, Inc.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

INDV$36.28+2.6%Stored close · as of Nov 2, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on the 26th day of February, 2026.

INDIVIOR PHARMACEUTICALS, INC. (Registrant)

By: /s/ Ryan Preblick

Ryan Preblick, Chief Financial Officer

/s/ Joseph CiaffoniChief Executive Officerand Executive DirectorFebruary 26, 2026
Joseph Ciaffoni(Principal Executive Officer)
/s/ Ryan PreblickChief Financial OfficerFebruary 26, 2026
Ryan Preblick(Principal Financial Officer)
/s/ Woodrow AndersonSenior Vice President—Group ControllerFebruary 26, 2026
Woodrow Anderson(Principal Accounting Officer)
/s/ Dr. David WheadonChair andIndependent Non-Executive DirectorFebruary 26, 2026
Dr. David Wheadon
/s/ Dr. Keith HumphreysIndependent Non-Executive DirectorFebruary 26, 2026
Dr. Keith Humphreys
/s/ Stuart (Tony) KingsleyIndependent Non-Executive DirectorFebruary 26, 2026
Stuart (Tony) Kingsley
/s/ Daniel NinivaggiIndependent Non-Executive DirectorFebruary 26, 2026
Daniel Ninivaggi
/s/ Barbara RyanIndependent Non-Executive DirectorFebruary 26, 2026
Barbara Ryan
/s/ Mark StejbachIndependent Non-Executive DirectorFebruary 26, 2026
Mark Stejbach
/s/ Juliet ThompsonIndependent Non-Executive DirectorFebruary 26, 2026
Juliet Thompson
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.